Advanced Search


Study ID Status Title Patient Level Data
115362 Completed A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease. Study Listed on
115373 Completed Safety and immunogenicity study of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in healthy toddlers aged 12-23 months
115374 Completed Assessment of safety of GlaxoSmithKline (GSK) Biologicals’ combined reduced antigen content diphtheria-tetanus toxoids and acellular pertussis vaccine (dTPa), Boostrix when administered according to the approved Prescribing Information in Korea
115375 Completed Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™ Study Listed on
115376 Completed A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy (currently untreated) Study Listed on
115377 Completed A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents Study Listed on
115380 Completed A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects. Study Listed on
115381 Completed An Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (dolutegravir, DTG) in Healthy Japanese Subjects
115385 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects Study Listed on
115387 Completed A single-centre, escalating dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a slow intravenous infusion of GW328267X in healthy volunteers Study Listed on
115389 Completed Safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix-IPV+HibTM) in healthy Vietnamese toddlers Study Listed on
115391 Completed A meta-analysis of dose-exposure relationships for gabapentin following the administration of HORIZANT® or NEURONTIN®
115393 Withdrawn A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis
115398 Completed Airflow Limitation in Cardiac Diseases in Europe
115400 Terminated A prospective, exploratory observational study evaluating specific biomarkers in primary invasive breast cancer and their modulation by standard neoadjuvant therapy
115403 Completed A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement Study Listed on
115408 Completed A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease Study Listed on
115409 Completed A multi-center, randomized, active controlled, double-blind, parallel group comparison study and subsequent open-label study of GSK548470 in patients with compensated chronic hepatitis B untreated with nucleic acid analogue
115411 Completed Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 year old females Study Listed on
115415 Completed An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK2789869A and GSK2789868A administered in adults 21 to 64 years of age Study Listed on
115418 Completed A Phase IIIA study of immunogenicity and safety of GSK Biologicals’ quadrivalent split virion influenza vaccine FLU-Q-QIV in adults aged 18 years and older Study Listed on
115419 Completed A two part study to investigate the safety and tolerability, pharmacokinetics and pharmacodynamics of GSK2339345 in healthy subjects. Part A: an open label, dose escalating, rinse, gargle and spit study. Part B: a randomised, double-blind, placebo controlled, inhaled dose escalating study using nebulised lidocaine for blinding purposes. Study Listed on
115428 Completed A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
115429 Completed A follow-up study to evaluate the long-term persistence of GSK Biologicals’ candidate CMV vaccine administered to male adults
115433 Completed Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.